德孚在中国

9 9 6 5 3

论文已发表

提 交 论 文


注册即可获取德孚的最新动态

注 册



IF 收录期刊





更多详情 >>





已发表论文

多种小分子缀合物作为新的靶向传递载体用于治疗肿瘤

 

Authors Shan L, Liu M, Wu C, Zhao L, Li S, Xu L, Cao W, Gao G, Gu Y
Received 25 March 2015
Accepted for publication 13 May 2015
Published 1 September 2015 Volume 2015:10 Pages 5571—5591
DOI http://dx.doi.org/10.2147/IJN.S85402
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 4
Editor who approved publication:  Dr Lei Yang

 

Abstract: In response to the challenges of cancer chemotherapeutics, including poor physicochemical properties, low tumor targeting ability, and harmful side effects, we developed a new tumor-targeted multi-small molecule drug delivery platform. Using paclitaxel (PTX) as a model therapeutic, we prepared two prodrugs, ie, folic acid-fluorescein-5(6)-isothiocyanate-arginine-paclitaxel (FA-FITC-Arg-PTX) and folic acid-5-aminofluorescein-glutamic-paclitaxel (FA-5AF-Glu-PTX), composed of folic acid (FA, target), amino acids (Arg or Glu, linker), and fluorescent dye (fluorescein in vitro or near-infrared fluorescent dye in vivo) in order to better understand the mechanism of PTX prodrug targeting. In vitro and acute toxicity studies demonstrated the low toxicity of the prodrug formulations compared with the free drug. In vitro and in vivo studies indicated that folate receptor-mediated uptake of PTX-conjugated multi-small molecule carriers induced high antitumor activity. Notably, compared with free PTX and with PTX-loaded macromolecular carriers from our previous study, this multi-small molecule-conjugated strategy improved the water solubility, loading rate, targeting ability, antitumor activity, and toxicity profile of PTX. These results support the use of multi-small molecules as tumor-targeting drug delivery systems.
Keywords: multi-small molecules, paclitaxel, prodrugs, targeting, tumor therapy


Download Article[PDF]